TQC3927 / Sino Biopharm - LARVOL DELTA

Phase I Clinical Study of TQC3927 Inhaled Powder: Safety, Tolerability and Pharmacokinetics with Single-dose Escalation in Healthy Adult Individuals (ERS 2026) - P1 | "TQC3927 was generally well-tolerated with low plasma drug concentration and rapid metabolism, which might be a soft molecule warranting further clinical development as a treatment for COPD."

Clinical • First-in-human • P1 data • PK/PD data • Chronic Obstructive Pulmonary Disease • Dyslipidemia • Gastrointestinal Disorder • Hypertriglyceridemia • Immunology • Respiratory Diseases

TQC3927-II-01: A Clinical Trial Comparing TQC3927 Inhaled Powder With Glycopyrronium Bromide and Formoterol Inhaled Aerosol (Biovoping Lingchang) for the Treatment of Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - P2 | N=90 | Suspended | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Initiation date: Jul 2026 ➔ Dec 2026 | Not yet recruiting ➔ Suspended

Trial initiation date • Trial suspension • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

A Clinical Trial Comparing TQC3927 Inhaled Powder With Glycopyrronium Bromide and Formoterol Inhaled Aerosol (Biovoping® Lingchang®) for the Treatment of Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - P2 | N=90 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

New P2 trial • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

A Clinical Trial of TQC3927 Powder for Inhalation in Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - P1 | N=48 | Completed | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Recruiting ➔ Completed | Trial completion date: Jan 2026 ➔ Aug 2025 | Trial primary completion date: Dec 2025 ➔ Aug 2025

Trial completion • Trial completion date • Trial primary completion date • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

A Clinical Trial of TQC3927 Powder for Inhalation in Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

A Clinical Trial of TQC3927 Powder for Inhalation in Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - P1 | N=48 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

New P1 trial • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

A Study of TQC3927 Powder for Inhalation in Healthy Adult Subjects (clinicaltrials.gov) - P1 | N=60 | Completed | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting ➔ Completed | Trial completion date: Feb 2025 ➔ Aug 2024 | Trial primary completion date: Dec 2024 ➔ Aug 2024

Trial completion • Trial completion date • Trial primary completion date • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

A Study of TQC3927 Powder for Inhalation in Healthy Adult Subjects (clinicaltrials.gov) - P1 | N=60 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

New P1 trial • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases